GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (OTCPK:MDBIF) » Definitions » ROE % Adjusted to Book Value

TrivarX (TrivarX) ROE % Adjusted to Book Value : -33.43% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is TrivarX ROE % Adjusted to Book Value?

TrivarX's ROE % for the quarter that ended in Dec. 2023 was -29.42%. TrivarX's PB Ratio for the quarter that ended in Dec. 2023 was 0.88. TrivarX's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -33.43%.


TrivarX ROE % Adjusted to Book Value Historical Data

The historical data trend for TrivarX's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX ROE % Adjusted to Book Value Chart

TrivarX Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -163.47 -95.82 -12.44 -125.77 -53.04

TrivarX Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.61 -243.83 -15.55 -91.32 -33.43

Competitive Comparison of TrivarX's ROE % Adjusted to Book Value

For the Health Information Services subindustry, TrivarX's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TrivarX's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TrivarX's ROE % Adjusted to Book Value falls into.



TrivarX ROE % Adjusted to Book Value Calculation

TrivarX's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-44.55% / 0.84
=-53.04%

TrivarX's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-29.42% / 0.88
=-33.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TrivarX ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of TrivarX's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


TrivarX (TrivarX) Business Description

Traded in Other Exchanges
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.

TrivarX (TrivarX) Headlines

From GuruFocus

Medibio Announces Scientific Advisory Board

By Marketwired Marketwired 04-26-2018

Medibio Granted CE Mark Approval for MEBsleep

By PRNewswire PRNewswire 01-19-2021

Medibio Releases Corporate Health Product, ilumen™

By Marketwired Marketwired 10-03-2018

Departure of Managing Director & Chief Executive Officer

By Marketwired Marketwired 08-29-2018

Receipt of $3,146,835 R&D Tax Incentive Refund

By Marketwired Marketwired 10-15-2018

Medibio Announces Executive Leadership Changes

By Marketwired Marketwired 09-21-2018